NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC State") to support the continued research and development of HT-KIT, a novel therapeutic for the treatment mast cell cancers.
(PRNewsfoto/Hoth Therapeutics Inc.)
The research will be led by Dr. Glenn Cruse, Assistant Professor, and will focus on characterizing the HT-KIT dose and dosing frequency for treatment of aggressive mastocytosis and mast cell neoplasms using humanized tumor mouse models. In addition, the research will expand therapeutic potential of HT-KIT for the treatment of other cancers where aberrant cKIT signaling contributes to the cancer progression, such as gastrointestinal stromal tumors (GIST) and acute myeloid leukemia (AML).
"We are pleased to announce the continuation of our development of HT-KIT after our earlier announcement of beginning API and drug product manufacturing," said Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics, Inc. "We remain focused on pushing this important cancer therapeutic through to the clinic. The research conducted by Dr. Cruse and NC State will help direct the continued development and clinical planning of this potentially life-saving therapy."
About HT-KITHT-KIT is a new molecular entity (NME) under development for treatment of mast cell derived cancers and anaphylaxis. HT-KIT was developed Dr. Glenn Cruse, Assistant Professor at North Carolina State University. The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT in mast cells, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as gastrointestinal stromal tumors and mast cell-derived cancers (mast cell leukemia and mast cell sarcoma). Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis. The same target, KIT, also plays a key role in mast cell-mediated anaphylaxis, a serious allergic reaction that is rapid in onset and may cause death. Anaphylaxis typically occurs after exposure to an external allergen that results in an immediate and severe immune response.
Story continues
About Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking StatementThis press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:LR Advisors LLCEmail: investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-a-sponsored-research-agreement-to-further-develop-novel-mrna-cancer-therapeutic-ht-kit-301425327.html
SOURCE Hoth Therapeutics, Inc.
Continued here:
Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT - Yahoo Finance
- Israeli-Based 3D-Printed Lab-Grown Meat Company is Building World's ... - December 27th, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- A Look Into the Next Century After 100 Years of Insulin - Cureus - October 13th, 2022
- Grafting and Budding Nursery Crop Plants - North Carolina State University - October 4th, 2022
- Lifting up NC Teachers of the Year and TFA alumni - EdNC - August 22nd, 2022
- Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans - VegNews - July 27th, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more - KYMA - July 19th, 2022
- Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation... - July 3rd, 2022
- W-S organization working on regenerative therapies for 40 organs, tissues - WRAL TechWire - July 3rd, 2022
- BioRestorative Therapies Annou - GuruFocus.com - July 3rd, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety - WYFF4 Greenville - June 13th, 2022
- Pediatric Urologist Dr. Anthony Atala to Receive 2022 Jacobson Innovation Award of the American College of Surgeons for Pioneering Work in... - June 13th, 2022
- The Soybean Plant | NC State Extension Publications - June 4th, 2022
- A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - June 4th, 2022
- Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting - Yahoo... - April 6th, 2022
- Cytovia and Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader ... - The Bakersfield Californian - November 22nd, 2021
- Study Underway to Evaluate New PD-1/CD3 Antibody in T-cell Lymphoma - Targeted Oncology - October 28th, 2021
- What it means to be the worlds first IVF baby - THE WEEK - August 31st, 2021
- Cellectis Announces Participation in Five Investor Conferences - Yahoo Finance - August 31st, 2021
- Nanodecoy Therapy is an Effective Alternative to Neutralize SARS-CoV-2 Virus - AZoNano - June 23rd, 2021
- 'Nanodecoy' Therapy Binds and Neutralizes SARS-CoV-2 Virus - NC State News - June 23rd, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Invisible pest causes more than $1 billion in crop losses - The Albany Herald - January 13th, 2021
- Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion - Reuters - January 13th, 2021
- Chancellor Harold L. Martin, on His Plan to Safely Open the Nation's Largest HCBU During COVID-19 - TIME - August 23rd, 2020
- Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk - August 23rd, 2020
- Study finds little evidence to back cord-blood therapy for autism - Spectrum - June 12th, 2020
- Balding men could grow hair back in weeks thanks to 'miracle potion' - Daily Star - May 19th, 2020
- Treatment in clinical trial offers options to woman fighting return of cancer (+ video) - WRAL Tech Wire - February 28th, 2020
- Searching for the 'big break' that could turn stem cells into a weapon against dementia - Genetic Literacy Project - February 28th, 2020
- Why Some COVID-19 Cases Are Worse than Others - The Scientist - February 28th, 2020
- The Future of Bioprinting Research Has a New Road Map - 3DPrint.com - February 14th, 2020
- Top Florida Medical Spa, Amnion of Florida, Partners With Merakris Therapeutics to Advance Their Non-Surgical Treatment Options - Business Wire - December 11th, 2019
- Synthetic Stem Cells Market Is Expecting Revolutionary Growth 2019 with Top Key Players: North Carolina State University (NCSU), Zhengzhou University... - December 6th, 2019
- Clinic pitches unproven treatments to desperate patients, with tips on raising the cash - Seattle Times - December 6th, 2019
- Reviewing vTv Therapeutics Inc. (VTVT)'s and Asterias Biotherapeutics Inc. (:)'s results - MS Wkly - October 27th, 2019
- Reviewing BioCryst Pharmaceuticals Inc. (BCRX)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 27th, 2019
- Global Synthetic Stem Cells Market Estimated to Reach USD 42 Million By 2025 - Daily Market Updates - September 29th, 2019
- Global Synthetic Stem Cells Market to Accumulate Revenues Worth US $42 Million By 2025 - ZMR News Research - September 24th, 2019
- Heal Yourself: How Exosome Therapy Can Repair Age-Damaged Skin - Market Research Finance - September 24th, 2019
- Cesca Therapeutics Inc. (KOOL) Can't Be More Safe. Trades Significantly Higher - Invest Tribune - September 24th, 2019
- Stem Cell Winston Salem North Carolina 27150 - April 5th, 2019
- Clinical Trial for Autism - cordbloodbank.com - March 8th, 2019
- Stem Cell Chapel Hill North Carolina 27514 - February 11th, 2019
- Alumna to compete for Miss America crown on Sunday - UNCSA - February 3rd, 2019
- Stem Cell Therapy Latest Research Charlotte, North Carolina - December 2nd, 2018
- Stem Cell Therapy North Carolina | Regenerative Medicine ... - October 4th, 2018
- Bone Marrow Transplant | Durham, Raleigh, North Carolina ... - July 24th, 2018
- Charlotte, North Carolina - Stem Cells Transplant Institute - July 15th, 2018
- Stem Cell Greensboro North Carolina 27455 - July 15th, 2018
- Spotlights Archive | The University of North Carolina at ... - October 15th, 2017
- Stem Cells in Focus - Blog - Closer Look at Stem Cells - October 10th, 2017
- Avalon Advisors Has Decreased Its Comcast Cmn Class (CMCSA) Position; Neuralstem (CUR)'s Sentiment Is 0 - High Point Observer - September 6th, 2017
- Former basketball star Greg Friel in fight of his life - Fosters - Foster's Daily Democrat - August 15th, 2017
- Lung fibrosis? Stem cell therapy holds promise - The Hindu - The Hindu - August 11th, 2017
- Stem cells may treat lung fibrosis diseases - Futurity: Research News - August 11th, 2017
- CRISPR Edits Genome of Human Embryos - Alzforum - August 11th, 2017
- Cary NC Stem Cell Treatment | Cary North Carolina Cancer ... - November 16th, 2016
- Cato - Research Triangle Park, Durham, North Carolina - August 21st, 2016
- Biotechnology Teacher Resources Online | North Carolina ... - August 19th, 2016
- Stem Cell Research in North Carolina ... Whats Really ... - August 5th, 2016
- JCI - Type 2 alveolar cells are stem cells in adult lung - October 19th, 2015
- Cary North Carolina Stem Cell Research | Cary NC Stem Cell ... - July 2nd, 2015
- Core labs | North Carolina Biotech Center - April 29th, 2015
- Image: Human endothelial cells experiment bound for ISS - February 26th, 2015
- COPD Prognosis Stem Cells Canada, COPD Alternative ... - February 17th, 2015
- Cancer Care Northwest Stem Cell Transplantation - January 10th, 2015
- Dying child approved for new treatment testing - January 2nd, 2015
- New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit - November 5th, 2014
- Committee on Development, Regeneration, and Stem Cell ... - October 31st, 2014
- Local doctor uses stem cells to heal - October 29th, 2014
- Study Offers Fertility Preservation Option to Young Boys with Cancer - October 1st, 2014
- Fayetteville North Carolina Stem Cell Research ... - September 16th, 2014
- Charlotte NC Resources - Stem Cells: Get Facts on Uses ... - September 1st, 2014
- For the first time, researchers isolate adult stem cells ... - August 26th, 2014
- The Man Who Grew Eyes From Scratch - August 26th, 2014
- Carolina Stem Cell Treatment Center | carolina stem ... - August 22nd, 2014
- North Carolina Stem Cell Treatment | Stem Cell Treatments - August 22nd, 2014